Wealthquest Corp bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 5,441 shares of the company’s stock, valued at approximately $5,847,000. Eli Lilly and Company comprises about 0.4% of Wealthquest Corp’s holdings, making the stock its 23rd biggest position.
A number of other hedge funds have also bought and sold shares of the business. Weinberger Asset Management Inc purchased a new position in Eli Lilly and Company in the 4th quarter worth about $224,000. William Blair Investment Management LLC raised its position in Eli Lilly and Company by 108.2% in the 4th quarter. William Blair Investment Management LLC now owns 32,016 shares of the company’s stock worth $34,407,000 after buying an additional 16,641 shares during the last quarter. Prospera Financial Services Inc raised its position in Eli Lilly and Company by 1.8% in the 4th quarter. Prospera Financial Services Inc now owns 54,090 shares of the company’s stock worth $58,148,000 after buying an additional 980 shares during the last quarter. Darden Wealth Group Inc raised its position in Eli Lilly and Company by 9.8% in the 4th quarter. Darden Wealth Group Inc now owns 1,125 shares of the company’s stock worth $1,209,000 after buying an additional 100 shares during the last quarter. Finally, Clune & Associates LTD. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $214,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Trading Up 0.1%
LLY stock opened at $1,066.59 on Monday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 37.89, a PEG ratio of 1.16 and a beta of 0.48. The business has a 50 day simple moving average of $942.87 and a two-hundred day simple moving average of $1,004.53.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.
Analyst Ratings Changes
LLY has been the subject of several research reports. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Barclays upped their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Daiwa Securities Group upped their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,220.37.
Get Our Latest Research Report on Eli Lilly and Company
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly’s retatrutide reported strong Phase 3 results, boosting confidence in its obesity pipeline and long-term growth prospects. Eli Lilly (LLY) Announces Positive Phase 3 Results for Obesity Treatment Retatrutide
- Positive Sentiment: Reports say Eli Lilly has now captured roughly 60% of the U.S. weight-loss drug market, underscoring commercial momentum versus Novo Nordisk. Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here’s What You Need to Know.
- Positive Sentiment: Gamco’s Mario Gabelli and ARK’s Cathie Wood both reportedly boosted their LLY holdings, which can be viewed as a vote of confidence from notable investors. Gamco Investors’ Mario Gabelli Boosts Eli Lilly Stake ARK Investment’s Cathie Wood boosts Eli Lilly stake by 12,676 shares
- Neutral Sentiment: Several other funds reported small stake changes in LLY, but these appear to be routine portfolio adjustments rather than a major fundamental signal.
- Negative Sentiment: Lilly also remains in the spotlight for legal overhangs, including a lawsuit tied to alleged drug reimbursement fraud and another dispute involving church leaders, which could create headline risk. Lilly accuses church-linked pharmacies, wholesalers and more of running $200M+ rebate fraud scheme
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
